Institutional shares held 111 Million
978K calls
881K puts
Total value of holdings $35.9B
$317M calls
$286M puts
Market Cap $39.9B
123,028,000 Shares Out.
Institutional ownership 90.06%
# of Institutions 722


Latest Institutional Activity in ALNY

Top Purchases

Q2 2025
Central Pacific Bank Trust Division Shares Held: 3.02K ($978K)
Q2 2025
Versant Capital Management, Inc Shares Held: 387 ($125K)
Q2 2025
Nbc Securities, Inc. Shares Held: 12 ($3.89K)
Q1 2025
Wellington Management Group LLP Shares Held: 2.61M ($846M)
Q1 2025
Nuveen, LLC Shares Held: 883K ($286M)

Top Sells

Q2 2025
E. Ohman J:Or Asset Management Ab Shares Held: 5.7K ($1.85M)
Q2 2025
Parallel Advisors, LLC Shares Held: 817 ($265K)
Q2 2025
Nova Wealth Management, Inc. Shares Held: 8 ($2.59K)
Q1 2025
Baillie Gifford & CO Shares Held: 3.66M ($1.19B)
Q1 2025
Ci Private Wealth, LLC Shares Held: 42.7K ($13.8M)

About ALNY

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.


Insider Transactions at ALNY

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
345K Shares
From 27 Insiders
Grant, award, or other acquisition 125K shares
Exercise of conversion of derivative security 220K shares
Open market or private purchase 36 shares
Sell / Disposition
311K Shares
From 11 Insiders
Open market or private sale 262K shares
Bona fide gift 49.7K shares

Track Institutional and Insider Activities on ALNY

Follow ALNYLAM PHARMACEUTICALS, INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ALNY shares.

Notify only if

Insider Trading

Get notified when an Alnylam Pharmaceuticals, Inc. insider buys or sells ALNY shares.

Notify only if

News

Receive news related to ALNYLAM PHARMACEUTICALS, INC.

Track Activities on ALNY